反応式
Br[CH2:2][C:3]([C:5]1[CH:14]=[CH:13][C:12]2[C:11]([CH3:16])([CH3:15])[CH2:10][CH2:9][C:8]([CH3:18])([CH3:17])[C:7]=2[CH:6]=1)=O.[OH:19][CH:20]1[CH2:25][CH2:24][N:23]([C:26](=[S:28])[NH2:27])[CH2:22][CH2:21]1>>[CH3:15][C:11]1([CH3:16])[CH2:10][CH2:9][C:8]([CH3:17])([CH3:18])[C:7]2[CH:6]=[C:5]([C:3]3[N:27]=[C:26]([N:23]4[CH2:24][CH2:25][CH:20]([OH:19])[CH2:21][CH2:22]4)[S:28][CH:2]=3)[CH:14]=[CH:13][C:12]1=2参加物
3
実験手順
The preparation was carried out as already described starting from 397 mg (0.94 mmol) of 2-bromo-1-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethanone and 100 mg (0.62 mmol) of 4-hydroxypiperidine-1-carbothioic acid amide from step a. The product was purified by means of preparative HPLC and is in the form of the hydrochloride.
後処理
- customThe product was purified by means of preparative HPLC
出典と根拠
- ORDレコード
- ord-cb75d02964c044f18c3f1ad37356523b
- 出典データセット
- uspto-grants-2014_12
- 特許番号
- US08907098B2
関連ノート
読み込み中…